AveXis Inc. (AVXS) Trading Down 6.4%
AveXis Inc. (NASDAQ:AVXS) shares traded down 6.4% during mid-day trading on Thursday . The company traded as low as $37.23 and last traded at $37.27, with a volume of 194,814 shares traded. The stock had previously closed at $39.80.
A number of research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Chardan Capital reaffirmed a “buy” rating and set a $60.00 price target on shares of AveXis in a report on Friday, August 12th. Jefferies Group raised shares of AveXis from a “hold” rating to a “buy” rating and set a $42.00 price target for the company in a report on Friday, August 12th. Wells Fargo & Co. raised shares of AveXis from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 17th. Finally, Goldman Sachs Group Inc. upped their price target on shares of AveXis from $28.00 to $47.00 and gave the stock a “buy” rating in a report on Friday, May 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $45.40.
The company’s 50-day moving average is $37.49 and its 200 day moving average is $32.03. The company’s market capitalization is $820.64 million.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.68) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.09. On average, analysts expect that AveXis Inc. will post ($3.38) earnings per share for the current year.
AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.